|Videos|June 8, 2017

What Are Pleuromutilin Antibiotics and How Do They Work?

Thomas File, MD, MSc explains what pleuromutilin antibiotics are and how they work.

Thomas File, MD, MSc, Chair of Infectious Disease Division, Summa Health in Akron, Ohio, explains what pleuromutilin antibiotics are and how they work.

Interview Transcript (slightly modified for readability):

“Pleuromutilins are a class of antimicrobial agents that have been recently developed for systemic administration for us to treat patients with certain infections. [They] work by inhibiting protein synthesis, but [they] have a unique mechanism of action which is different than other drugs that inhibit protein synthesis such that it is going to be effective against many pathogens that are resistant to these other drugs.”

DISCLOSURES: Dr. File is a consultant and on the Scientific Advisory Boards for Achaogen; Allergan; Bayer; Cempra; The Medicine’s Company; Merck; MotifBio; Nabriva; Paratek; Zavante.


Related to this article

The Prospective Emergence of XDR Shigella Beyond High-Risk Groups
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
FAQ: XDR Shigella
Here is some important information around this pathogen and the intestinal infection.